Financhill
Back

Aprea Therapeutics Quote, Financials, Valuation and Earnings

Aprea Therapeutics Price Quote

$4.05
+0.14 (+3.58%)
(Updated: November 1, 2024 at 2:30 PM ET)

Aprea Therapeutics Key Stats

Sell
4
Aprea Therapeutics (APRE) is a Sell

Day range:
$3.82 - $4.17
52-week range:
$2.15 - $8.85
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.83%

Volume:
13.9K
Avg. volume:
36.4K
1-year change:
16.37%
Market cap:
$21.2M
Revenue:
$0
EPS:
$-3.03

How Much Does Aprea Therapeutics Make?

Data Unavailable

Is Aprea Therapeutics Growing As A Company?

Data Unavailable

Aprea Therapeutics Stock Price Performance

What Is Aprea Therapeutics 52-Week High & Low?

Aprea Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Aprea Therapeutics?

Is Aprea Therapeutics Cash Flow Positive?

  • What Is APRE Cash Flow From Operations?
    Cash flow from operations (TTM) is -$13.6M
  • What Is Aprea Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $14.7M
  • What Is Aprea Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$108.6K

Aprea Therapeutics Return On Invested Capital

Data Unavailable

Aprea Therapeutics Earnings Date & Stock Price

Aprea Therapeutics Competitors

  • Who Are Aprea Therapeutics's Competitors?
    Below is a list of companies who compete with Aprea Therapeutics or are related in some way:
    • Aethlon Medical Inc (AEMD)
    • Brainstorm Cell Therapeutics Inc (BCLI)
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Aprea Therapeutics Dividend Yield

Aprea Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 4.13%
Revenue: 0% 1584.88%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 15.67
Upside from Last Price: 300.68%

Major Shareholders

  • How many APRE shares are owned by institutional investors?
    2.5M APRE shares are owned by institutional investors
  • How many APRE shares are owned by insiders?
    1.2M APRE shares are owned by insiders